Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone payments.
Moderna said the companies intend to combine Immatics' T-cell redirecting cancer therapies with its mRNA technology.
Immatics will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments that could exceed $1.7 billion, Moderna said.
https://finance.yahoo.com/news/1-moderna-immatics-jointly-cancer-113125165.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.